Zimmer Biomet touts 7-year results in Mobi-C cervical disc trial

Zimmer Biomet (NYSE:ZBH) yesterday released seven-year follow-up results from a study of its Mobi-C cervical disc device designed for total disc replacement procedures, touting lower pain, maintained motion range and other benefits.

Results from the study were published in the International Journal of Spine Surgery, the Warsaw, Ind.-based company said.

In the study, researchers compared the use of the the Mobi-C cervical total disc replacement system against the previous standard of care, anterior cervical discectomy and fusion, in nearly 600 patients over seven years.

Results indicated that use of the Mobi-C during cTDR procedures was associated with lower pain scores, a maintained range of motion, less adjacent level degeneration and subsequent adjacent level surgeries and a lower rate of secondary surgery when compared to ACDF.

Follow-up rates in the trial ranged from 73.5% to 84.4%, with overall success rates for patients undergoing two-level cTDR of 60.8% versus 34.6% for ACDF. Success rates were more similar between one-level patients, with 55.2% for cTDR patients and 50% for ACDF.

Researchers indicated that the composite success analysis showed the two-level cTDR was superior over ACDF, and that one-level cTDR was non-inferior versus ACDF.

Results also indicated a higher Neck Disability Index success rate in two-level cTDR over ACDF at 79% versus 58%, respectively. More than 86% of patients who received two-level cTDR and 73.9% of patients who underwent ACDF were “very satisfied” with the outcomes at seven years.

“This study further validates the strengths of Mobi-C as a solution for cervical total disc replacement. The positive clinical outcomes remain consistent with previous findings, mainly that Mobi-C continues to deliver positive patient outcomes including efficacy, safety, patient satisfaction and fewer follow-up surgeries. It is particularly important that the clinical effectiveness of cTDR versus ACDF becomes more apparent when treatment increases from one to two levels, indicating a significant benefit for Mobi-C in two-level procedures, which affects an estimated one in three cervical disc patients,” Zimmer Biomet spine division GM Joe Ross said in a press release.

Earlier this week, Zimmer Biomet said it will participate in the US Dept. of Energy’s Better Buildings, Better Plants energy reduction programs as it looks to reduce its carbon footprint in the US and Puerto Rico.

The post Zimmer Biomet touts 7-year results in Mobi-C cervical disc trial appeared first on MassDevice.

from MassDevice https://ift.tt/2J6PqTO